T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$2.03B |
| 2 |
Rockwell Automation
ROK
|
+$1.44B |
| 3 |
Autodesk
ADSK
|
+$1.15B |
| 4 |
Citigroup
C
|
+$975M |
| 5 |
ConocoPhillips
COP
|
+$967M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.59B |
| 2 |
GE Aerospace
GE
|
+$1.78B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.38B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 5 |
Philip Morris
PM
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.21% |
| 2 | Healthcare | 15.42% |
| 3 | Financials | 10.99% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
776
CRISPR Therapeutics
CRSP
$5.22B
| $40.9M | 0.01% |
600,234
-264,112
| -31% | -$18.9M |
|
777
Church & Dwight Co
CHD
$24B
| $40.9M | 0.01% |
392,168
+1,335
| +0.3% | +$134K |
|
778
Mirum Pharmaceuticals
MIRM
$6.02B
| $40.1M | ﹤0.01% |
1,597,506
+432,824
| +37% | +$11.9M |
|
779
Robinhood
HOOD
$89.3B
| $40.1M | ﹤0.01% |
1,991,586
+1,251,495
| +169% | +$17.5M |
|
780
Pultegroup
PHM
$24.9B
| $40M | ﹤0.01% |
331,553
+12,164
| +4% | +$1.31M |
|
781
The Bancorp
TBBK
$2.82B
| $39.8M | ﹤0.01% |
1,189,149
-1,626
| -0.1% | -$64.7K |
|
782
Regions Financial
RF
$27B
| $39.7M | ﹤0.01% |
1,884,539
-12,096
| -0.6% | -$229K |
|
|
CTRA
783
DELISTED
Coterra Energy
CTRA
| $39.6M | ﹤0.01% |
1,421,129
+1,201
| +0.1% | +$30.8K |
|
784
Charter Communications
CHTR
$18.7B
| $39.4M | ﹤0.01% |
135,701
-484,228
| -78% | -$156M |
|
785
RLI Corp
RLI
$5.87B
| $39.4M | ﹤0.01% |
530,730
+66,870
| +14% | +$4.76M |
|
786
Entrada Therapeutics
TRDA
$290M
| $39M | ﹤0.01% |
2,753,357
-256,316
| -9% | -$3.62M |
|
787
Xometry
XMTR
$5.42B
| $38.9M | ﹤0.01% |
2,300,879
-410,789
| -15% | -$11.1M |
|
788
Take-Two Interactive
TTWO
$45.2B
| $38.6M | ﹤0.01% |
260,196
+3,583
| +1% | +$556K |
|
789
Graphic Packaging
GPK
$3.51B
| $38.2M | ﹤0.01% |
1,309,141
-3,754
| -0.3% | -$98.2K |
|
790
SM Energy
SM
$7.71B
| $38.1M | ﹤0.01% |
764,118
+124,450
| +19% | +$5.09M |
|
|
DAWN
791
DELISTED
Day One Biopharmaceuticals
DAWN
| $38M | ﹤0.01% |
2,299,764
-17,000
| -0.7% | -$254K |
|
|
SMAR
792
DELISTED
Smartsheet Inc.
SMAR
| $38M | ﹤0.01% |
985,915
+8,815
| +0.9% | +$385K |
|
793
Expedia Group
EXPE
$39.4B
| $37.9M | ﹤0.01% |
275,430
+97,825
| +55% | +$13.9M |
|
794
eBay
EBAY
$46.5B
| $37.9M | ﹤0.01% |
717,798
+20,712
| +3% | +$941K |
|
795
Q2 Holdings
QTWO
$4.13B
| $37.8M | ﹤0.01% |
719,767
+683,957
| +1,910% | +$30.9M |
|
796
Advanced Energy
AEIS
$13.2B
| $37.6M | ﹤0.01% |
368,378
-1,497
| -0.4% | -$153K |
|
797
Constellium
CSTM
$3.95B
| $37.6M | ﹤0.01% |
1,698,900
+21,569
| +1% | +$418K |
|
|
IGMS
798
DELISTED
IGM Biosciences
IGMS
| $37.5M | ﹤0.01% |
3,888,023
+628,001
| +19% | +$7.28M |
|
799
NovoCure
NVCR
$2.02B
| $37.2M | ﹤0.01% |
2,378,940
+125,715
| +6% | +$1.85M |
|
800
Applovin
APP
$105B
| $37.2M | ﹤0.01% |
536,937
+295,251
| +122% | +$15.6M |
|
Similar funds
T. Rowe Price Associates's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Associates held 3,021 positions worth $816B, up 9.6% from $744B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2024 filing shows 108 new, 1,941 increased, 738 reduced and 64 closed positions. Its largest new stake was GE Vernova: 2,687,194 shares worth $367M. The largest sale was NVIDIA, an estimated $2.59B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2024 buy was GE Vernova: 2,687,194 shares worth $367M.
- T. Rowe Price Associates added most to Fortinet in Q1 2024, an estimated $2.03B increase.
- T. Rowe Price Associates's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $2.59B.
- T. Rowe Price Associates fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $621M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $816B portfolio in Q1 2024.
- T. Rowe Price Associates opened 108 new positions and closed 64 in Q1 2024.
- T. Rowe Price Associates's portfolio value rose 9.6% quarter-over-quarter to $816B.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.